Tekla Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $10.6M | Hold |
112,908
| – | – | 0.42% | 55 |
|
|
2023
Q1 | $11.4M | Hold |
112,908
| – | – | 0.44% | 51 |
|
|
2022
Q4 | $13.5M | Sell |
112,908
-55,200
| -33% | -$6.47M | 0.51% | 46 |
|
|
2022
Q3 | $17.9M | Hold |
168,108
| – | – | 0.73% | 39 |
|
|
2022
Q2 | $16.4M | Buy |
168,108
+43,499
| +35% | +$4.01M | 0.64% | 40 |
|
|
2022
Q1 | $11.7M | Hold |
124,609
| – | – | 0.41% | 58 |
|
|
2021
Q4 | $10.6M | Hold |
124,609
| – | – | 0.34% | 66 |
|
|
2021
Q3 | $12M | Sell |
124,609
-88,282
| -41% | -$8.34M | 0.38% | 63 |
|
|
2021
Q2 | $20.7M | Hold |
212,891
| – | – | 0.67% | 40 |
|
|
2021
Q1 | $20.7M | Sell |
212,891
-81,343
| -28% | -$8.53M | 0.71% | 37 |
|
|
2020
Q4 | $28.2M | Buy |
294,234
+231,031
| +366% | +$22.3M | 0.99% | 27 |
|
|
2020
Q3 | $6.08M | Sell |
63,203
-142,947
| -69% | -$16.5M | 0.23% | 96 |
|
|
2020
Q2 | $25.1M | Hold |
206,150
| – | – | 0.96% | 25 |
|
|
2020
Q1 | $17.8M | Buy |
206,150
+13,108
| +7% | +$1.28M | 0.81% | 29 |
|
|
2019
Q4 | $20.8M | Sell |
193,042
-13,780
| -7% | -$1.44M | 0.78% | 32 |
|
|
2019
Q3 | $18.6M | Sell |
206,822
-256
| -0.1% | -$23.9K | 0.81% | 32 |
|
|
2019
Q2 | $17.5M | Sell |
207,078
-14,600
| -7% | -$1.2M | 0.71% | 34 |
|
|
2019
Q1 | $19.5M | Buy |
221,678
+5,384
| +2% | +$450K | 0.79% | 31 |
|
|
2018
Q4 | $15.4M | Buy |
216,294
+3,664
| +2% | +$351K | 0.66% | 37 |
|
|
2018
Q3 | $26.1M | Sell |
212,630
-57,139
| -21% | -$6.48M | 0.95% | 26 |
|
|
2018
Q2 | $26.5M | Sell |
269,769
-9,650
| -3% | -$864K | 1.01% | 26 |
|
|
2018
Q1 | $23.2M | Sell |
279,419
-45,648
| -14% | -$3.85M | 0.9% | 27 |
|
|
2017
Q4 | $25.2M | Sell |
325,067
-237,400
| -42% | -$16.2M | 0.97% | 27 |
|
|
2017
Q3 | $34.5M | Hold |
562,467
| – | – | 1.23% | 21 |
|
|
2017
Q2 | $25.9M | Buy |
562,467
+116,393
| +26% | +$5.65M | 0.96% | 26 |
|
|
2017
Q1 | $19.3M | Buy |
446,074
+54,205
| +14% | +$2.32M | 0.75% | 29 |
|
|
2016
Q4 | $15.2M | Sell |
391,869
-264,753
| -40% | -$12M | 0.65% | 34 |
|
|
2016
Q3 | $33.3M | Sell |
656,622
-110,400
| -14% | -$5.5M | 1.28% | 24 |
|
|
2016
Q2 | $34.9M | Buy |
767,022
+455,562
| +146% | +$21M | 1.42% | 20 |
|
|
2016
Q1 | $12.3M | Hold |
311,460
| – | – | 0.52% | 46 |
|
|
2015
Q4 | $17.6M | Sell |
311,460
-64,400
| -17% | -$3.27M | 0.64% | 31 |
|
|
2015
Q3 | $15M | Hold |
375,860
| – | – | 0.54% | 38 |
|
|
2015
Q2 | $18M | Sell |
375,860
-125,290
| -25% | -$5.31M | 0.65% | 33 |
|
|
2015
Q1 | $19.9M | Sell |
501,150
-499,200
| -50% | -$17.9M | 0.79% | 32 |
|
|
2014
Q4 | $22.3M | Sell |
1,000,350
-281,600
| -22% | -$5.34M | 1.05% | 25 |
|
|
2014
Q3 | $20.1M | Buy |
1,281,950
+491,460
| +62% | +$7.35M | 0.94% | 28 |
|
|
2014
Q2 | $11.7M | Buy |
790,490
+362,700
| +85% | +$5.12M | 1.08% | 25 |
|
|
2014
Q1 | $6.89M | Hold |
427,790
| – | – | 0.69% | 38 |
|
|
2013
Q4 | $4M | Sell |
427,790
-142,597
| -25% | -$1.39M | 0.42% | 40 |
|
|
2013
Q3 | $6.46M | Sell |
570,387
-137,603
| -19% | -$1.89M | 0.72% | 35 |
|
|
2013
Q2 | $9.47M | Buy |
+707,990
| New | +$8.7M | 1.29% | 23 |
|
Other funds holding NBIX
BG
AC
Tekla Capital Management's NBIX Position: Q2 2023 in Review
Tekla Capital Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2023 at 112,908 shares worth $10.6M. The position accounts for 0.42% of the portfolio, ranked #55.
Tekla Capital Management first reported a position in NBIX in Q2 2013 and has held it in 41 quarters since. The position peaked at $34.9M in Q2 2016. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.
- Tekla Capital Management held 112,908 shares of Neurocrine Biosciences worth $10.6M as of Q2 2023.
- Tekla Capital Management left its Neurocrine Biosciences share count unchanged in Q2 2023.
- Neurocrine Biosciences made up 0.42% of Tekla Capital Management's portfolio in Q2 2023, its #55 holding.
- Tekla Capital Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 41 quarters since.
- Tekla Capital Management's Neurocrine Biosciences position peaked at $34.9M in Q2 2016.
- 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.
Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.